Claris Lifesciences rose 2.19% to Rs 202.60 at 10:40 IST on BSE after the company said its board will meet on 7 January 2014, to consider a proposal for buyback of the equity shares.
The company made the announcement after market hours on Thursday, 2 January 2014.
Meanwhile, the BSE Sensex was down 99.39 points, or 0.48%, to 20,788.94.
On BSE, so far 1.56 lakh shares were traded in the counter, compared with an average volume of 6.56 lakh shares in the past one quarter.
The stock hit a high of Rs 209.80 and a low of Rs 202.30 so far during the day. The stock hit a 52-week high of Rs 232 on 3 April 2013. The stock hit a 52-week low of Rs 142.05 on 18 June 2013.
The stock had outperformed the market over the past one month till 2 January 2014, rising 12.10% compared with the Sensex's 0.05% fall. The scrip had, however, underperformed the market in past one quarter, rising 5.62% as against Sensex's 7.03% rise.
The small-cap company has an equity capital of Rs 63.82 crore. Face value per share is Rs 10.
Claris Lifesciences' consolidated net profit rose 33.59% to Rs 33.01 crore on 33.18% decline in net sales to Rs 129.58 crore in the quarter ended September 2013 over the quarter ended September 2012.
Claris Lifesciences is a sterile injectables pharmaceutical company with a market presence across 100 countries worldwide. The company manufactures and markets products across various therapeutic segments. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses.
Powered by Capital Market - Live News
